Deutsche Bank notes from the company’s R&D briefing that CSL believes the development of anti-FcRn drugs will have a place in simple autoimmune disease but is not convinced of the long-term safety issues.
Ig also has a faster treatment effect on simple autoimmune disease, such as Immune Thrombocytopenia. CSL is currently developing a recombinant Fc multimer which may help with replacing volumes of Ig lost to anti-FcRn drugs. Hold retained. Target is $207.
Sector: Pharmaceuticals, Biotechnology & Life Sciences.
Target price is $207.00.Current Price is $179.24. Difference: $27.76 – (brackets indicate current price is over target). If CSL meets the Deutsche Bank target it will return approximately 13% (excluding dividends, fees and charges – negative figures indicate an expected loss).